Clinical trials: open to volunteers, in Nigeria
Colorectal Cancer
Tislelizumab in People With Colorectal Cancer
The researchers are doing this study to find out whether tislelizumab is an effective treatment for people with colorectal cancer who are living in Nigeria. The researchers will also look at the safety of the study drug.
- Trial name
- NCT06529523
- Testing
- Tislelizumab
- Where
- 3 sites in United States, Nigeria
- Volunteers
- 40 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Dietary Sources of Sodium, Population Sodium Intake
Evaluating Implementation and Scale-Up of Nigeria's National Sodium Reduction Program
The NaSS aims to assess the extent to which the SHAKE program is implemented within Nigeria by the Nigerian Agency for Food and Drug Administration and Control (NAFDAC) using a type III hybrid, mixed method study design.
- Trial name
- NaSS (NCT04765865)
- Testing
- SHAKE Package
- Where
- 3 sites in Nigeria
- Volunteers
- 1,350 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Hypertension, Diabetes
Genetics of Type 2 Diabetes in West Africans
Background: Type 2 diabetes (T2D) and associated complications are major contributors to the global disease burden. T2D is already a major health threat in populations in developed countries and is rapidly taking hold in the…
- Trial name
- NCT00837122
- Where
- 5 sites in Ghana, Nigeria
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- National Human Genome Research Institute (NHGRI)
Cardiovascular Diseases
Cardiovascular Disease Multimorbidity
This is a hybrid type II effectiveness-implementation trial using a parallel cluster randomized design. Thirty primary healthcare centers (PHCs) in Akwa Ibom State, Nigeria, will be randomized in a 1:1 ratio to the implementation…
- Trial name
- NCT07909395
- Testing
- HEARTS, PF
- Where
- 2 sites in United States, Nigeria
- Volunteers
- 1,050 people
- Sponsor
- NYU Langone Health
Acute Kidney Injury, Fluid Overload
Assessment of Worldwide Acute Kidney Injury Epidemiology in Neonates 2.0
There is a growing focus on short- and long-term kidney health in neonates, including those with acute kidney injury (AKI). AKI occurs commonly in the Neonatal Intensive Care Unit (NICU) and is associated with adverse outcomes.
- Conditions
- Acute Kidney Injury, Fluid Overload, Prematurity Complications, Risk Factors
- Trial name
- AWAKEN 2 (NCT06823115)
- Where
- 125 sites in United States, Argentina and 31 more
- Volunteers
- 8,000 people
- Sponsor
- Indiana University
Sickle Cell Disease
Hydroxyurea Optimisation in Sickle Cell Disease
The wide interindividual variability in clinical response to hydroxyurea therapy in the management of sickle cell disease has limited its use.
- Trial name
- PHOENIX-NG (NCT07543289)
- Testing
- Hydroxyurea (HU)
- Where
- Nigeria
- Volunteers
- 100 people
- Sponsor
- Ochuko Orherhe
Lassa Fever
A Lassa Fever Vaccine Trial in Adults and Children Residing in West Africa
A Phase 2 Randomized, Double-Blinded, Placebo-Controlled Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of rVSV∆G-LASV-GPC Vaccine in Adults and Children Residing in West Africa
- Trial name
- NCT05868733
- Testing
- Day 1 Dose (2×106 pfu), Day 1 Dose (1×107 pfu), Day 1 Dose (2×10^5 pfu)
- Where
- 3 sites in Ghana, Liberia and 1 more
- Volunteers
- 530 people, healthy volunteers welcome
- Sponsor
- International AIDS Vaccine Initiative
Breast Cancer, Breast Cancer Female
Tablet-based Mobile Health Ultrasound for Point-of-care Breast Cancer Diagnosis in Nigeria (Mobile Health: Technology and Outcomes in Low and Middle-Income Countries)
The purpose of this study is to train Nigerian radiologists to perform ultrasound-guided breast biopsies. Researchers will use mHealth devices to create a sustainable and practical way of training radiologists in Nigeria to…
- Trial name
- NCT05561842
- Testing
- mHealth US-breast biopsy
- Where
- 8 sites in United States, Nigeria
- Volunteers
- 900 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Diabete Mellitus
Hypertension Treatment in Nigeria: Hypertension Diabetes Integration Study- Formative Aim 3
The purpose of the second phase of the Hypertension Treatment in Nigeria (HTN 2.0) Program is to build upon the success of the first phase of the HTN Program (2020-2023), which implemented the WHO HEARTS package across 60 primary…
- Trial name
- HTN2 (NCT07589387)
- Testing
- Implementation of program based on WHO HEARTS-D guidelines, Metformin, Glimepiride
- Where
- 10 sites in Nigeria
- Volunteers
- 2,800 people
- Sponsor
- Washington University School of Medicine
Hypertension (HTN)
Hypertension Treatment in Nigeria 2.0
The purpose of the second phase of the Hypertension Treatment in Nigeria (HTN 2.0) Program is to build upon the success of the first phase of the HTN Program (2020-2023), which implemented the WHO HEARTS package across 60 primary…
- Trial name
- HTN 2 (NCT07351162)
- Testing
- Implementation of a modified WHO HEARTS Hypertension Treatment Bundle
- Where
- 49 sites in Nigeria
- Volunteers
- 10,000 people
- Sponsor
- Washington University School of Medicine
Chronic Lung Diseases
Prospective Study on Antimicrobial RESIstance in Chronic Pulmonary DiseasE
This observational, multicentric prospective study aims to understand the prevalence and burden of antimicrobial resistance (AMR) in people with chronic lung diseases (CLD) across the globe, understanding also geographical…
- Trial name
- PRESIDE (NCT07874139)
- Where
- 68 sites in United States, Albania and 31 more
- Volunteers
- 683 people
- Sponsor
- Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Sickle Cell Disease
A Study to Evaluate the Pharmacokinetics and Safety of Etavopivat in Pediatric Patients With Sickle Cell Disease
The purpose of this study is to evaluate the pharmacokinetics and safety of etavopivat in paediatric participants with sickle cell disease (SCD).
- Trial name
- HIBISCUS KIDS (NCT06198712)
- Testing
- Etavopivat
- Where
- 18 sites in Canada, France and 5 more
- Volunteers
- 95 people
- Sponsor
- Forma Therapeutics, Inc.
Sickle Cell Disease, Thalassemia
A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia
Etavopivat is a new medicine under development for treating blood disorders like sickle cell disease and thalassaemia. Sickle cell disease and thalassaemia are inherited blood disorders that affect haemoglobin.
- Trial name
- FLORAL (NCT06609226)
- Testing
- Etavopivat A, Etavopivat B, Etavopivat C
- Where
- 107 sites in United States, Canada and 15 more
- Volunteers
- 480 people
- Sponsor
- Novo Nordisk A/S
Sickle Cell Disease
A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease
This study is conducted to confirm whether etavopivat works well at reducing the number of Vaso-occlusive crisis VOCs (sickle cell pain crises) caused by obstructions in blood vessels in adults and adolescents living with sickle…
- Trial name
- Hibiscus 2 (NCT06612268)
- Testing
- Etavopivat
- Where
- 175 sites in United States, Australia and 19 more
- Volunteers
- 510 people
- Sponsor
- Novo Nordisk A/S
Sickle Cell Disease
A Phase 2 Open-label Study to Evaluate the Activity of Etavopivat on Transcranial Doppler Velocities in Pediatric Patients With Sickle Cell Disease Who Are at Increased Risk for Primary Stroke
The study will test a new medicine, etavopivat, for sickle cell disease and see if it is safe and help-ful for participants with sickle cell disease who are at an increased risk of stroke.
- Trial name
- HIBISCUS 3 (NCT05953584)
- Testing
- Etavopivat, Hydroxyurea
- Where
- 9 sites in India, Nigeria and 1 more
- Volunteers
- 27 people
- Sponsor
- Forma Therapeutics, Inc.
Type 2 Diabetes, Hypertension
iCaReMe Global Registry: Multinational Real-world Evidence in Cardiorenal and Metabolic Diseases
To provide real world data on patient characteristics, disease management, healthcare utilization, and outcomes in patients with type 2 diabetes, Hypertension, Heart failure and/or Chronic kidney diseases
- Conditions
- Type 2 Diabetes, Hypertension, Chronic Kidney Disease, Heart Failure
- Trial name
- iCaReMe (NCT03549754)
- Where
- 76 sites in Brazil, Chile and 18 more
- Volunteers
- 35,000 people
- Sponsor
- AstraZeneca
Tuberculosis
Assessing Diagnostics At Point-of-care for Tuberculosis
Every year, more than 3 million people with TB remain undiagnosed and 1 million die. Better diagnostics are essential to reducing the enormous burden of TB worldwide.
- Trial name
- ADAPT (NCT05941052)
- Testing
- Tongue swab-based molecular assays
- Where
- 3 sites in Nigeria, Philippines and 1 more
- Volunteers
- 1,350 people
- Sponsor
- University of California, San Francisco
Cardiovascular Biomarkers, Preeclampsia (PE) Risk
A Study to Find and Confirm Blood-based Markers (Called Proteins) That May Show Early Heart Changes in Women With Preeclampsia, Even Before Symptoms Appear, and the Use of Heart Ultrasound (Echocardiography) to Look at Patterns of How the Heart Changes During Pregnancy in Women With Preeclampsia
The goal of this study is to find and confirm blood-based markers (called proteins) that may show early heart changes in women with preeclampsia, even before symptoms appear.
- Conditions
- Cardiovascular Biomarkers, Preeclampsia (PE) Risk, Preeclampsia (PE)
- Trial name
- PRECISE (NCT07463898)
- Testing
- No Intervention: Observational Cohort
- Where
- Nigeria
- Volunteers
- 172 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Breast Cancer
Tablet-based Mobile Health Ultrasound for Point-of-care Breast Cancer Diagnosis in Nigeria
The purpose of this study is to train Nigerian radiologists to perform ultrasound-guided breast biopsies on women that present to the hospital with a suspicious breast mass.
- Trial name
- NCT04501419
- Testing
- US-guided breast biopsy, Ultrasound-guided breast biopsy training program
- Where
- Nigeria
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Memorial Sloan Kettering Cancer Center
Sickle Cell Disease
A Phase 2/3 Study of Osivelotor in Adult and Adolescent Participants With SCD
The purpose of this study is to evaluate the safety, tolerability, efficacy, pharmacokinetics and pharmacodynamics of osivelotor.
- Trial name
- NCT05431088
- Testing
- Osivelotor
- Where
- 80 sites in United States, Brazil and 5 more
- Volunteers
- 389 people
- Sponsor
- Pfizer